Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.2055 | 0.5431 | 0.5431 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.2116 | 0.5612 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.3585 | 1 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.2116 | 0.5612 | 0.5 |
Trichomonas vaginalis | set domain proteins, putative | 0.027 | 0.0098 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3585 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.3524 | 0.9819 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3585 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3585 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.2116 | 0.5612 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3585 | 1 | 1 |
Onchocerca volvulus | 0.3585 | 1 | 1 | |
Brugia malayi | Pre-SET motif family protein | 0.0237 | 0 | 0.5 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.3585 | 1 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.2116 | 0.5612 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.3524 | 0.9819 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.2116 | 0.5612 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.3524 | 0.9819 | 0.9819 |
Loa Loa (eye worm) | hypothetical protein | 0.3585 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.3524 | 0.9819 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3524 | 0.9819 | 0.9706 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | < 90 % | Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 1 to 100 ug/mL after 7 days by resazurin reduction test | ChEMBL. | No reference |
IZ (functional) | < 10 mm | Antifungal activity against Candida albicans assessed as growth inhibition at 6.25 to 25 ug/ml after 3 to 4 days by agar well diffusion method | ChEMBL. | No reference |
IZ (functional) | < 10 mm | Antibacterial activity against Escherichia coli ATCC 24922 assessed as growth inhibition at 1.56 to 25 ug/ml after 3 to 4 days by agar well diffusion method | ChEMBL. | No reference |
MIC (functional) | = 5 ug ml-1 | Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 0.3125 to 5 ug/mL after 7 days by resazurin reduction test | ChEMBL. | No reference |
MIC (functional) | = 10 ug ml-1 | Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 1 to 100 ug/mL after 7 days by resazurin reduction test | ChEMBL. | No reference |
MIC (functional) | = 25 ug ml-1 | Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis assessed as growth inhibition at 0.3125 to 5 ug/mL after 7 days by resazurin reduction test | ChEMBL. | No reference |
MIC (functional) | = 25 ug ml-1 | Antibacterial activity against Escherichia coli ATCC 24922 assessed as growth inhibition after 16 to 18 hr by serial plate dilution method | ChEMBL. | No reference |
MIC (functional) | = 25 ug ml-1 | Antifungal activity against Candida albicans assessed as growth inhibition after 3 to 4 days by serial plate dilution method | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.